Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection (SEVO-COVID19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04359862
Recruitment Status : Terminated (Low recruitment ratio)
First Posted : April 24, 2020
Last Update Posted : July 27, 2021
Sponsor:
Information provided by (Responsible Party):
Fundación para la Investigación del Hospital Clínico de Valencia

Brief Summary:

It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study.

Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours.

Patients will be randomized to one of the treatment groups:

  • SEV group: 25 patients with Sevoflurane sedation by inhalation, starting at 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved (BIS 40-50)
  • PRO group: 25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)

Condition or disease Intervention/treatment Phase
Acute Respiratory Distress Syndrome COVID19 Infection Drug: Sevoflurane Drug: Propofol Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multicenter, national, randomized, 1:1 ratio, controlled, parallel, open study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection
Actual Study Start Date : April 16, 2020
Actual Primary Completion Date : March 31, 2021
Actual Study Completion Date : March 31, 2021


Arm Intervention/treatment
Experimental: SEVOFLURANE Group Drug: Sevoflurane
25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)

Active Comparator: PROPOFOL Group Drug: Propofol
25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)




Primary Outcome Measures :
  1. PaO2/FiO2 [ Time Frame: Day 2 ]
    To evaluate the effect of 48-hour treatment with inhaled sevoflurane on arterial oxygenation, assessed by PaO2/FiO2 on day two, in patients with ARDS-CoVid19


Secondary Outcome Measures :
  1. TNFα [ Time Frame: Day 2 ]
    To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19

  2. IL-1b [ Time Frame: Day 2 ]
    To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19

  3. IL-6 [ Time Frame: Day 2 ]
    To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19

  4. IL-8 [ Time Frame: Day 2 ]
    To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19

  5. Mortality [ Time Frame: Day 30 ]
    To evaluate the 30-day mortality.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years or more.
  • Diagnosis of Acute Respiratory Distress Syndrome caused by COVID19 infection.
  • Signature of Patient's Consent or Verbal Consent of Legal Representative

Exclusion Criteria:

  • Intracranial hypertension
  • Hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients
  • Current volume < 250ml
  • History of malignant hyperthermia
  • Liver failure
  • Neutropenia (<0.5x109)
  • Pregnant or lactating women
  • Have received chemotherapy in the last month since their inclusion in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04359862


Locations
Layout table for location information
Spain
Hospital Universitario Cruces
Barakaldo, Bizkaia, Spain, 48903
Hospital Universitario Ramón y Cajal
Madrid, Spain, 28034
Hospital Universitario La Paz
Madrid, Spain, 28046
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010
Hospital General Universitario de Valencia
Valencia, Spain, 46014
Sponsors and Collaborators
Fundación para la Investigación del Hospital Clínico de Valencia
Layout table for additonal information
Responsible Party: Fundación para la Investigación del Hospital Clínico de Valencia
ClinicalTrials.gov Identifier: NCT04359862    
Other Study ID Numbers: SEVO-COVID19
First Posted: April 24, 2020    Key Record Dates
Last Update Posted: July 27, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
COVID-19
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Syndrome
Disease
Pathologic Processes
Disease Attributes
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury
Propofol
Sevoflurane
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous